On February 25, 2026, dsm-firmenich announced that its PARSOL Shield (INCI: Bemotrizinol) was added to the Secondary Sunscreen Monograph at concentrations up to 6% by Health Canada. This marks an important regulatory advancement for the company’s sun protection technologies.
According to the company’s press release, PARSOL Shield has been permitted under Canada’s Primary Sunscreen Monograph, designating that sun protection is the main intended function of the product. The updated monograph allows the ingredient to be listed for use in products where sun protection plays a secondary role, such as daily-wear cosmetics and multifunctional skincare products.
“This milestone aligns with dsm-firmenich’s ongoing efforts in the United States to secure FDA approval of PARSOL Shield as a sunscreen active ingredient,” said Amy Ethier, PhD, regulatory affairs manager for the company’s North America division of Beauty & Care. “Health Canada’s decision to update the monograph reflects a strengthened industry alignment and reinforces the strong safety and efficacy profile of PARSOL Shield as a highly photo-stable, broad-spectrum UVA/UVB filter.”
dsm-firmenich’s press release claims that PARSOL Shield offers broad-spectrum performance at low concentrations, supported by strong compatibility and stability. Company officials hope this regulatory update will allow formulators enhanced flexibility to develop products that meet evolving consumer needs.
